Patients with myeloma whose tumor immune microenvironments had a more diverse baseline T-cell repertoire, fewer markers of immune cell exhaustion, and distinct changes to immune cell populations were more likely to have longer progression-free survival (PFS) after treatment with BCMA-targeted T-cell therapy.
Winship Cancer Institute of Emory University has been awarded a P01 program project grant from the National Cancer Institute (NCI), nearly $11 million dollars over five years, to support research aimed at improving the effectiveness of immunotherapy for lung cancer in patients.